Solasia Pharma KK
TSE:4597
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Solasia Pharma KK
Change in Working Capital
Solasia Pharma KK
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Solasia Pharma KK
TSE:4597
|
Change in Working Capital
-¥8m
|
CAGR 3-Years
76%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
SanBio Co Ltd
TSE:4592
|
Change in Working Capital
-¥157.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
GNI Group Ltd
TSE:2160
|
Change in Working Capital
-¥2.8B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
|
PeptiDream Inc
TSE:4587
|
Change in Working Capital
-¥10.3B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-32%
|
|
|
Takara Bio Inc
TSE:4974
|
Change in Working Capital
¥489m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
O
|
Oncolys Biopharma Inc
TSE:4588
|
Change in Working Capital
¥33.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-9%
|
|
Solasia Pharma KK
Glance View
Solasia Pharma KK engages in the development, sale, import and export of pharmaceutical products and medical devices. The company is headquartered in Minato-Ku, Tokyo-To and currently employs 77 full-time employees. The company went IPO on 2017-03-24. is a Japan-based pharmaceutical company. The firm is mainly engaged in the development, sale, importing and exporting of pharmaceutical products targeting commercialization in Japan, China and other Asian countries. The company focuses on commercializing assets in the oncology/hematology field, by developing products licensed from western pharmaceutical and biotech companies. The firm's main products include SP-01 Granisetron Transdermal Delivery System (Sancuso), SP-02 Darinaparsin (Zinapar, ZIO-101, and SP-03 Oral Medical Device (episil oral liquid).
See Also
What is Solasia Pharma KK's Change in Working Capital?
Change in Working Capital
-8m
JPY
Based on the financial report for Dec 31, 2025, Solasia Pharma KK's Change in Working Capital amounts to -8m JPY.
What is Solasia Pharma KK's Change in Working Capital growth rate?
Change in Working Capital CAGR 3Y
76%
Over the last year, the Change in Working Capital growth was 96%. The average annual Change in Working Capital growth rates for Solasia Pharma KK have been 76% over the past three years .
